Biotech Acquisition Company Warrant
BIOTW
BIOTW was delisted on the 2nd of February, 2023.
52 hedge funds and large institutions have $5.06M invested in Biotech Acquisition Company Warrant in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 9 closing their positions.
7% less funds holding
Funds holding: 56 → 52 (-4)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
40% less capital invested
Capital invested by funds: $8.44M → $5.06M (-$3.38M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$212K |
| 2 |
KSCM
Kamunting Street Capital Management
Miami Beach,
Florida
|
+$50.7K |
| 3 |
QGA
Q Global Advisors
Fort Worth,
Texas
|
+$43.2K |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$14.9K |
| 5 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$7.97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Ramius Advisors
New York
|
-$299K |
| 2 |
Blackstone Inc
New York
|
-$165K |
| 3 |
FTCM
Fir Tree Capital Management
New York
|
-$82K |
| 4 |
AGM
Alpine Global Management
New York
|
-$67K |
| 5 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
-$66K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OCAM
51
Owl Creek Asset Management
New York
| $2K | +$3.19K | +10,000 | New |
|
52
UBS Group
Zurich,
Switzerland
| $1K | -$61 | -190 | -7% |
|
|
RA
53
Ramius Advisors
New York
| – | -$299K | -452,674 | Closed |
|
|
54
Blackstone Inc
New York
| – | -$165K | -250,000 | Closed |
|
|
FTCM
55
Fir Tree Capital Management
New York
| – | -$82K | -125,409 | Closed |
|
|
AGM
56
Alpine Global Management
New York
| – | -$67K | -103,502 | Closed |
|
|
PSAMP
57
P. Schoenfeld Asset Management (PSAM)
New York
| – | -$66K | -100,000 | Closed |
|
|
GCL
58
Glazer Capital LLC
New York
| – | -$52K | -79,079 | Closed |
|
|
CCFM
59
Cohen & Co Financial Management
New York
| – | -$33K | -50,000 | Closed |
|
|
PCM
60
Prelude Capital Management
New York
| – | -$12K | -18,154 | Closed |
|
|
MIG
61
Mariner Investment Group
Harrison,
New York
| – | -$7K | -10,000 | Closed |
|
BIOTW Hedge Fund Activity: Q1 2022 in Review
52 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q1 2022, worth a combined $5.06M — down 40% from $8.44M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BIOTW and 5 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was HGC Investment Management, adding an estimated $212K. The largest seller was Ramius Advisors, exiting entirely with an estimated $299K sold.
- 52 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q1 2022, down from 56 in Q4 2021.
- Funds reported $5.06M of Biotech Acquisition Company Warrant stock for Q1 2022, down 40% quarter-over-quarter.
- 5 funds opened new Biotech Acquisition Company Warrant positions in Q1 2022 and 9 closed out, a net change of -4 holders.
- The largest Biotech Acquisition Company Warrant buyer in Q1 2022 was HGC Investment Management, an estimated $212K added.
- The largest Biotech Acquisition Company Warrant seller in Q1 2022 was Ramius Advisors, an estimated $299K sold.
Based on aggregated 13F filings for Q1 2022.